Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Protalix BioTherapeutics (PLX) Cost of Revenue (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Cost of Revenue data on record, last reported at $8.3 million in Q3 2025.

  • For Q3 2025, Cost of Revenue fell 0.61% year-over-year to $8.3 million; the TTM value through Sep 2025 reached $26.3 million, down 10.34%, while the annual FY2024 figure was $24.3 million, 5.82% up from the prior year.
  • Cost of Revenue reached $8.3 million in Q3 2025 per PLX's latest filing, up from $5.9 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $9.5 million in Q2 2024 and bottomed at $2.4 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $5.6 million, with a median of $4.9 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: skyrocketed 269.46% in 2023, then crashed 56.12% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $3.1 million in 2021, then dropped by 23.86% to $2.4 million in 2022, then surged by 269.46% to $8.9 million in 2023, then plummeted by 56.12% to $3.9 million in 2024, then skyrocketed by 114.2% to $8.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $8.3 million in Q3 2025, $5.9 million in Q2 2025, and $8.2 million in Q1 2025.